Drug Type ASO |
Synonyms |
Target |
Mechanism PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization CiVi Biopharma, Inc.Startup |
Active Organization CiVi Biopharma, Inc.Startup |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lipid Metabolism Disorders | Phase 1 | US | CiVi Biopharma, Inc.Startup | 13 Mar 2022 |